Heart failure with reduced ejection fraction serves as a prototypical example in which advances in scientific discovery have not been fully realized in clinical practice. In recent years, stepwise progress in discovery science has afforded the availability of several disease-modifying therapies.1 Complete uptake of contemporary multidrug regimens is estimated to provide significant improvements in longevity and event-free survival.2 However, deep, pervasive gaps have remained in the optimal adoption of these therapies.3 Similar implementation gaps exist across other prevalent cardiometabolic conditions, including diabetes, chronic kidney disease, atherosclerotic cardiovascular disease, and obesity. These implementation shortcomings have limited the population-level benefit that these therapies might offer.4
Bhatt AS, Solomon SD, Vaduganathan M. Prioritizing Dissemination and Implementation Science in Cardiometabolic Medicine: CONNECTing the Dots. JAMA. 2021;326(4):311–313. doi:10.1001/jama.2021.9847
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: